Home

Insights

Orchid Pharma Ltd P/E Ratio

Orchid Pharma Ltd P/E Ratio

download
stocks purchased

₹ 0.2 Cr

Volume transacted

stocks purchased

2.2 K

stocks traded

Image

Orchid Pharma Ltd

NSE: ORCHPHARMA

PE

55.2

Last updated : 12 Jun 09:26 AM

Key Highlights

    The P/E Ratio of Orchid Pharma Ltd is 55.2 as of 12 Jun 09:26 AM .a1#The P/E Ratio of Orchid Pharma Ltd changed from 0.7 on March 2019 to 33.9 on March 2023 . This represents a CAGR of 117.28% over 5 years. a1#The Latest Trading Price of Orchid Pharma Ltd is ₹ 1062 as of 11 Jun 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 11.3. The PE Ratio of Finance industry is 21.7. The PE Ratio of IT - Software industry is 28.9. The PE Ratio of Pharmaceuticals industry is 102.9. The PE Ratio of Retail industry is 142.7. The PE Ratio of Textiles industry is 7.2. In 2024a1#The Market Cap of Orchid Pharma Ltd changed from ₹ 47.42 crore on March 2019 to ₹ 1568 crore on March 2023 . This represents a CAGR of 101.34% over 5 years. a1#The Revenue of Orchid Pharma Ltd changed from ₹ 133.92 crore to ₹ 230.46 crore over 8 quarters. This represents a CAGR of 31.18% a1#The EBITDA of Orchid Pharma Ltd changed from ₹ 15.38 crore to ₹ 42.28 crore over 8 quarters. This represents a CAGR of 65.80% a1#The Net Profit of Orchid Pharma Ltd changed from ₹ -14.09 crore to ₹ 33.5 crore over 8 quarters. This represents a CAGR of NaN% a1#The Dividend Payout of Orchid Pharma Ltd changed from 0 % on March 2019 to 0 % on March 2023 . This represents a CAGR of 0.0% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '190.7
Mar '200
Mar '210
Mar '220
Mar '2333.9

Fundamental Metrics

Market Cap

5,389 Cr

EPS

18.2

P/E Ratio (TTM) *

55.2

P/B Ratio (TTM) *

4.3

Day’s High

1074.9

Day’s Low

1044.75

DTE *

0.1

ROE *

7.9

52 Week High

1358.8

52 Week Low

412.0

ROCE *

8.3

* All values are consolidated

* All values are consolidated

Image

Orchid Pharma Ltd

NSE: ORCHPHARMA

PRICE

1062.7

5.30 (0.50%)

stock direction

Last updated : 11 Jun 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Orchid Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

Asset Value vs Market Value

Market Value

5,084

Asset Value

587

7.7 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Key Valuation Metric

Earnings

91 Cr

55.2 X

PE Ratio

Market Cap

₹5084Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

91 Cr

55.2 X

PE Ratio

Market Cap

₹5084Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Orchid Pharma Ltd PE Ratio Calculation

  • The Price-to-Earnings (PE) ratio, also known as the P/E Ratio, is a fundamental financial metric used to assess the valuation of a company's stock in relation to its earnings performance. For Orchid Pharma Ltd, the PE Ratio is calculated as follows:

P/E Ratio

=

Market Capitalization

Net Income

  • Given the current market conditions, Orchid Pharma Ltd's Share Price stands at 1062.7. The Earnings per Share (Diluted) for the trailing twelve months (TTM) ending in 2024-06-11T00:00:00 is 18.17. Substituting the values into the formula, PE Ratio becomes as follows: PE Ratio = 1062.7/ 18.17= 55.17.

P/E Ratio

=

Stock Price

Earning Per Share

  • This indicates that Orchid Pharma Ltd's stock is trading at approximately 55.17 times its earnings per share for the trailing twelve months. Alternatively, the PE Ratio can also be computed using the company's overall financial performance: PE Ratio = Market Cap / Net Income. Where Market Cap represents the total market capitalization of the company, and Net Income signifies the total earnings after expenses and taxes.

Understanding Orchid Pharma Ltd’s PE Ratio (BSE: ORCHPHARMA)

    The Price-to-Earnings (PE) ratio, used to assess Orchid Pharma Ltd's stock (BSE: ORCHPHARMA), indicates how many years it would take for the company to earn back the stock price. If a company earns ₹2 per share annually and its stock trades at ₹30, the PE ratio is 15, signifying a 15-year payback period assuming steady earnings. Earnings fluctuate, affecting the payback period, Growing earnings shorten the recovery time while declining earnings extend it. Shareholders favor shorter payback periods, preferring lower PE stocks. Among stocks with the same PE ratio, faster-growing businesses are preferred. A company with losses makes the PE ratio meaningless. Peter Lynch introduced the PEG ratio to compare stocks with different growth rates, dividing the PE ratio by the growth rate. A company is considered fairly valued when its PE ratio matches its growth rate. The PE ratio, applicable across industries, measures stock valuation based on earnings power. It indicates how quickly an investment can be recouped. Unlike the PB ratio, which assesses valuation based on the balance sheet, the PE ratio focuses on earnings. Overall, the PE ratio provides insights into stock valuation, aligning with investors' preference for faster returns.

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '1947
Mar '200
Mar '2110062
Mar '221160
Mar '231569

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22134
Sep '22171
Dec '22169
Mar '22251
Jun '23185
Sep '23207
Dec '23228
Mar '23230

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '2215
Sep '2224
Dec '2223
Mar '2274
Jun '2324
Sep '2332
Dec '2343
Mar '2342

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '22-14
Sep '22-3
Dec '227
Mar '2259
Jun '2311
Sep '2320
Dec '2330
Mar '2334

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '190
Mar '200
Mar '210
Mar '220
Mar '230

* All values are a in %

About Orchid Pharma Ltd

About Orchid Pharma Ltd

    Orchid Pharma Ltd., is one of the leading pharmaceutical companies in India head quartered in Chennai and involved in development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals with exports spanning over 40 countries. Orchid's world class manufacturing infrastructure include USFDA compliant API and Finished Dosage Form facilities at Chennai in India. The Company has dedicated state-of-art and GLP compliant R&D infrastructure for Process Research, Drug Discovery and Pharmaceutical Research at Chennai. The Company is a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well as in drug discovery, which was incorporated on 1st July 1992 as a 100% Export Oriented Unit (EOU). Orchid has two manufacturing sites for APIs (at Alathur near Chennai and at Aurangabad, near Mumbai) and three manufacturing sites for Dosage forms (at Irungattukottai and Alathur in Chennai), besides two R&D centres (at Sholinganallur and Irungattukottai, Chennai), all are state-of-the-art and have several international regulatory approvals, including the US FDA and UK MHRA. Orchid's API facilities are ISO certified for their quality, environmental management and operational health and safety systems. Orchid has a Joint Venture in China for manufacturing sterile APIs. The Company commenced its operation in the year 1994, also in the same year; orchid had entered into an agreement with SBD Laboratories Italy for technology for keeping production in sterile condition. Orchid became the youngest Indian pharmaceutical company to be awarded the ISO 9002 certification in 1997. During the same year of 1997, the company made a tie-up with Technology Innovative Industry of Italy and also launched a range of new products in the steriles category. In 1998, Orchid, along with Cipla and Ranbaxy, had received approval from the Drug Controller of India (DCI) for the manufacture and export of sildenafil citrate, the main ingredient in Viagra, the drug developed by Pfizer to treat human male erectile dysfunction; by the way it had entered into the formulation market. The Trophy for Excellent Performance in Exports was awarded to the company as part of the National Export Awards Programme for the year 1998-99. The initial range of products was launched by the company in 1999, which includes three injectable cephalosporin formulations and two coprescription analgesics of the NSAID category. These are Tax-O-bid (Cefotaxime injection), Cefogram (Ceftriaxone injection), Orzid (Ceftazidime injection), Orchidol (Tramadol tablets) and N-Ltd (Nimesulide dispersible tablets. In the year 2000, Orchid had signed a Memorandum of Understanding (MoU) with the Mumbai-based Ajanta Pharma Ltd to acquire the latter's bulk drugs manufacturing plant located at Aurangabad. During the year 2001, the company had issued foreign currency convertible bonds to International finance Corporation. Orchid had inked a 50:50 joint venture alliance pact with a California-based drug discovery research firm Bexel Biotechnology Inc in the year of 2002. During the year 2003, the company had acquired Mano Pharmaceuticals for a consideration of Rs.26 crores and also in the same year received a formal approval from US Food and Drug Administration for Cephalaxin. Orchid signed a pact with Par Pharmaceuticals Inc in 2004 to market oral cephalosporin formulations in US market. In 2005, the company made pact with Alpharma Inc to market oral non-antibiotic formulations in US & European markets and also entered into agreement with STADA Pharmaceuticals, Inc (USA). In 2006, Orchid had signed a deal with Biovitrum in drug discovery field. The Company received approval from the US FDA for its ANDAs (abbreviated new drug application) for Cefdinir for capsules 300 mg and Cefdinir for oral suspension in July 2007. In April 2008, Orchid formed a wholly owned subsidiary Orchid Pharma Japan K K (Orchid Japan) to foray into the high potential Japanese generics market and in August of the same year 2008 received approvals of its marketing authorization (MA) for piperacillin and tazobactam for injection for marketing in the EU countries. The Company made a strategic research collaboration and license agreement with Merck & Co in September 2008 focused on the discovery, development and commercialization of novel agents for the treatment of bacterial and fungal infections. During 2009, Company undertook the development and manufacture of an anti-coagulant drug candidate initially discovered and developed through Phase I by Merck & Co., Inc., USA. Towards this end, it invested in Diakron Pharmaceuticals Inc., a US based drug discovery and development company which has an exclusive license agreement with Merck for the compound. The Company and Merck & Co., Inc, USA, established a strategic research collaboration and license agreement focused on the discovery, development and commercialisation of novel agents for the treatment of bacterial and fungal infections. During 2008-09, the DCP application of Tazobactum Piperacillin was successfully completed and the product was launched in the EU market in distribution partnership with Hospira. The Company accelerated Orchid's proprietary drug discovery business by developing several additional hits and leads in the therapeutic areas of inflammation, oncology, diabetes and anti-infectives. The Company sold/ transferred Generic Injectable Formulations Business, including the facility situated at Irungattukottai near Chennai to Hospira Healthcare India Private Limited, a subsidiary of Hospira Inc., USA based on the approval from various Government agencies and the shareholders. The business transfer proposal was built on the existing product development and commercialisation relationship between Hospira and Orchid, which covered several product-market segments which completed in 2009-10. During 2010-11, Company acquired Karalex Pharma, LLC, a US based generic marketing and sales services Company headquartered in New Jersey through Company's step down subsidiary Orchid Pharma Inc. The Company formed a new subsidiary namely Orchid Pharma, Inc., in the USA. It increased stake in Diakron Pharmaceuticals Inc. which holds 64.55% in the Company. Orchid Pharmaceuticals (South Africa) Pty Ltd. was incorporated as a wholly owned subsidiary of the Company to register and market Company's products in South Africa. During 2011-12, Orchid Research Laboratories Limited (ORLL) a wholly-owned subsidiary was merged with Company effective from April 01, 2010 i.e. the Appointed Date' which was sanctioned by The Hon'ble High Court of Madras and the Scheme of Amalgamation became effective with the Registrar of Companies, Chennai, Tamil Nadu from March 30, 2012. Bexel became a 100% subsidiary of Company upon amalgamation of Orchid Research Laboratories Limited with Company. The Company increased its stake in Diakron Pharmaceuticals Inc., and holds 76.4% in the Company in 2011-12. During the year 2012-13, company incorporated Orchid Pharma Singapore Private Limited a wholly owned subsidiary in Singapore to deal in pharmaceuticals products. The Business Transfer Agreement (BTA) with Hospira for the transfer of Aurangabad Penems and Penicillin Plant and R&D facility at Shozhanganallur was completed on July 4, 2014. In January 2017, Company launched a new product, 'Rasagiline' in the US market. According to the Resolution Plan approved by the Hon'ble National Company Law Tribunal (NCLT) has, by its Order dated June 27, 2019 and the order of the Hon'ble Supreme Court vide its Order dated February 28, 2020, Dhanuka Laboratories Limited (DLL), the successful Resolution Applicant, implemented the Resolution Plan on March 31, 2020. DLL infused the funds as per the terms of the resolution plan through a special purpose vehicle, Dhanuka Pharmaceuticals Private Limited. The special purpose vehicle was later on merged with the Company as per the terms of the approved resolution plan. Thus the Company became a subsidiary of M/s Dhanuka Laboratories Limited with effect from March 31, 2020. The Company subscribed to 2,600 equity shares of Rs.10/- each constituting 26% of paid up equity share capital of M/s OrBion Pharmaceuticals Private Limited during FY 2021-2022 and consequently, the Company became an Associate of Company. Orchid Bio-Pharma limited was incorporated as Indian Wholly owned Subsidiary (WoS) of the Company on March 24, 2022.

Orchid Pharma Ltd News Hub

News

Orchid Pharma receives DCGI approval for Enmetazobactam

Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manuf...

Read more

06 Jun 202413:06

News

Orchid Pharma gains on DCGI nod for new antibiotic drug combination

DCGI has also granted permission to manufacture and market finished dosage form (FDF) of C...

Read more

06 Jun 202412:38

News

Orchid Pharma slides as PAT slumps 49% YoY in Q4 FY24

However, income from operations rose 3.43% YoY to Rs 217.10 crore in the quarter ended 31 ...

Read more

24 May 202412:56

News

Orchid Pharma to conduct board meeting

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 23 May 2024 ...

Read more

17 May 202414:12

News

Orchid Pharma receives USFDA approval for Enmetazobactam

Orchid Pharma has received approval by the United States Food and Drug Administration (USF...

Read more

23 Feb 202417:12

News

Orchid Pharma jumps after receiving USFDA nod for Exblifep injections

This New Drug Approval (NDA) allows the use of Exblifep (Cefepime and Enmetazobactam) as a...

Read more

23 Feb 202416:18

Product Composition by Percentage (Revenue)

FAQs for PE of Orchid Pharma Ltd

What is Orchid Pharma Ltd current share price?

The current market price of Orchid Pharma Ltd as of June 12, 2024 is ₹1062.70.

What is Orchid Pharma Ltd's market cap?

Orchid Pharma Ltd's market capitalisation stood at ₹5,084 Cr as of June 12, 2024

What are Orchid Pharma Ltd's total net assets?

According to Orchid Pharma Ltd's most recent financial filings, the company's net assets total ₹587.1 Cr.

Is Orchid Pharma Ltd making a profit or loss?

Orchid Pharma Ltd's net Profit as of June 12, 2024 is close to ₹91 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199